

May 02, 2017

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001.

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.

Rel: Scrip Code: 532296

Rel: Scrip Name: GLENMARK

Dear Sirs,

Sub:- Board Meeting

We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations And Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Thursday, May 11, 2017 to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the year ended March 31, 2017 and to consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2017.

Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from March 24, 2017 to May 15, 2017 (both days inclusive) for the purpose of approval of Standalone and Consolidated Audited Financial Results for the Year ended March 31, 2017.

The above is for your information.

Thanking you.

Yours faithfully,
For Glenmark Pharmaceuticals Limited



Harish Kuber
Company Secretary Compliance Officer

Tel: 4018 9999 / 4018 9879
Fax: 4018 9986 (Legal & Secretarial Dept.)